VERONICA SPANDLER: Open Payments
NPI 1023626314 · SAN FRANCISCO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$421 in 14 payments from 7 companies in 2025. Trend: 2023 $434 · 2024 $566 · 2025 $421
Food & beverage: $421
| Company | Payments | Amount |
|---|---|---|
| Eisai Inc. | 3 | $140 |
| AstraZeneca Pharmaceuticals LP | 4 | $87 |
| Merck Sharp & Dohme LLC | 2 | $69 |
| ARRAY BIOPHARMA INC | 2 | $50 |
| ADC THERAPEUTICS AMERICA, INC. | 1 | $34 |
| Daiichi Sankyo Inc. | 1 | $21 |
| Novartis Pharmaceuticals Corporation | 1 | $20 |
Products named: Lenvima, KEYTRUDA, BRAFTOVI, ZYNLONTA, LYNPARZA, DATROWAY, KISQALI, TAGRISSO.
Industry payments across CA — which companies pay providers there.
